POETYK PSO-1 and PSO-2 trial results seen at the EADV meeting, studying Tyk2 inhibitor, deucravacitinib vs PBO or apremi
Tweet Content
POETYK PSO-1 and PSO-2 trial results seen at the EADV meeting, studying Tyk2 inhibitor, deucravacitinib vs PBO or apremilast in 666 & 1020 plaque psoriasis pts. Wk 16 PASI 75 higher in DEUC ((59%, 54%) vs Otezla (35%, 40%) vs PBO(13%,9%) https://t.co/qok68Kbb6J
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off